Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 4 (2007), Issue 4 (April)

1. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
   J Clin Oncol, 25(10): 1232-8. [Abstract] [Full-text]
2. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
   Oncologist, 12(3): 253-70. [Abstract] [Full-text]
3. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination.
   Cancer Res, 67(7): 3406-11. [Abstract] [Full-text]
4. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials.
   Cancer. [Abstract] [Full-text]
5. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
   J Natl Cancer Inst, 99(8): 628-38. [Abstract] [Full-text]
6. Standardization of HER2 testing: results of an international proficiency-testing ring study.
   Mod Pathol, 20(5): 584-91. [Abstract] [Full-text]
7. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes.
   Exp Cell Res, 313(8): 1588-601. [Abstract] [Full-text]
8. Role of tumor markers in patients with solid cancers: A critical review.
   Eur J Intern Med, 18(3): 175-184. [Abstract] [Full-text]
9. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
   Nat Rev Cancer, 7(5): 332-44. [Abstract] [Full-text]
10. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
    Int J Cancer, 121(1): 157-64. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.